Cryoablation for Advanced and Refractory Desmoid Tumors

University Hospital, Strasbourg, France30 enrolled

Overview

Desmoid tumors, also called aggressive fibromatosis, are rare, locally invasive tumors with no potential for metastasis. The incidence is approximately 2 to 4 per million per year in the general population. The "watch and wait" policy is the standard of care for newly diagnosed patients in Europe. Patients who progress have first-line medical treatment, surgery is no longer the treatment because there is a high rate of recurrence (\> 60%) and radiotherapy is not very suitable because the patients are often young and the tumors are large. Cryoablation seems to be an effective therapeutic option that should be evaluated.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Desmoid Tumors

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion criteria: * Adult patient (≥18 years old) * Having undergone cryoablation for an advanced desmoid tumor refractory to medical treatment * Having not expressed their opposition, after being informed, to the reuse of their data for the purposes of this research. Exclusion criteria: * Subject who expressed their opposition to participating in the study * Patient already included in another ongoing study * Subject under guardianship or curatorship * Subject under safeguard of justice

Locations (1)

Service d'Imagerie Interventionnelle - CHU de Strasbourg - France

Strasbourg, France

RECRUITING

Outcomes

Primary Outcomes

Progression-free survival assessed using RECIST(Response evaluation criteria in solid tumors) criteria

Time frame: at 6 months after cryoablation

Central Contacts

Pierre AULOGE, MD

CONTACT

33 3 69 55 15 26 pierre.auloge@chru-strasbourg.fr

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.